MDM2 and neoplasm: Recent evidence from studies of milademetan in intimal sarcoma suggests that cyclin-dependent kinase inhibitor 2A (CDKN2A) loss and amplified twist-related protein 1 (TWIST1) may serve as additional biomarkers associated with enhanced anti-tumor activity in MDM2-amplified tumors (Koyama et al., 2023).